DBV Technologies (NASDAQ:DBVT – Get Free Report) and Beam Therapeutics (NASDAQ:BEAM – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.
Analyst Ratings
This is a summary of recent recommendations and price targets for DBV Technologies and Beam Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| DBV Technologies | 1 | 1 | 5 | 0 | 2.57 |
| Beam Therapeutics | 1 | 2 | 10 | 0 | 2.69 |
DBV Technologies presently has a consensus target price of $48.50, suggesting a potential upside of 304.67%. Beam Therapeutics has a consensus target price of $49.00, suggesting a potential upside of 109.43%. Given DBV Technologies’ higher probable upside, research analysts plainly believe DBV Technologies is more favorable than Beam Therapeutics.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| DBV Technologies | -3,506.53% | -119.33% | -84.43% |
| Beam Therapeutics | -54.75% | -30.71% | -24.07% |
Risk and Volatility
DBV Technologies has a beta of -0.95, suggesting that its share price is 195% less volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.22, suggesting that its share price is 122% more volatile than the S&P 500.
Earnings & Valuation
This table compares DBV Technologies and Beam Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| DBV Technologies | $5.64 million | 133.62 | -$146.95 million | ($3.51) | -3.41 |
| Beam Therapeutics | $139.74 million | 17.29 | -$79.99 million | ($0.86) | -27.21 |
Beam Therapeutics has higher revenue and earnings than DBV Technologies. Beam Therapeutics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 1.1% of DBV Technologies shares are held by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Beam Therapeutics beats DBV Technologies on 11 of the 14 factors compared between the two stocks.
About DBV Technologies
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
About Beam Therapeutics
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
